메릴랜드의 크론병 임상 시험
크론병 관련 연구 15개가 메릴랜드 내 여러 지역에서 참여자를 모집하고 있습니다.
메릴랜드의 도시
공식 연구 텍스트(영어)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT03816345A Study of SL-325 in Crohn's Disease Patients
- Clinical Trial Site, Glen Burnie
피험자 모집 중2상
18세 ~ 80세 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07753850Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
- National Institutes of Health Clinical Center, Bethesda
피험자 모집 중관찰 연구
18세 ~ 85세 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT07619547A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Walter Reed National Military Medical Center ( Site 5006), Bethesda
피험자 모집 중3상
16세 ~ 80세 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT06430801Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Capital Digestive Care - Chevy Chase, Chevy Chase
피험자 모집 중3상
18세 ~ 70세 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06937099A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Chevy Chase Clinical Research, Chevy Chase
- Woodholme Gastroenterology Associates, Glen Burnie
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT07196722A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Woodholme Gastroenterology Associates, Glen Burnie
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT07499232An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
- National Institutes of Health Clinical Center, Bethesda
피험자 모집 중1/2상
18세 ~ 65세 · 모든 성별 · 2026. 11. 2. 업데이트됨 · NCT03167437A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Woodholme Gastroenterology Associates, Glen Burnie
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 11. 2. 업데이트됨 · NCT06233461A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Capital Digestive Care, Chevy Chase
- Woodholme Gastroenterology, Glen Burnie
피험자 모집 중4상
18세 ~ 80세 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT06581328An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Mercy Medical Center, Baltimore-Site Number: 8400117, Baltimore
- Mid-Atlantic GI Research, LLC-Site Number: 8400106, Laurel
피험자 모집 중3상
16세 ~ 80세 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT07184931Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Metropolitan Gastroenterology Group - Chevy Chase /ID# 265877, Chevy Chase
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06548542Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Mercy Medical Center, Baltimore
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 8. 5. 업데이트됨 · NCT07237516A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- Woodholme Gastroenterology Associates, Glen Burnie
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 5. 22. 업데이트됨 · NCT06764615A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Johns Hopkins University, Baltimore
피험자 모집 중3상
2세 ~ 17세 · 모든 성별 · 2026. 5. 5. 업데이트됨 · NCT04779320ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.